Nanoscale drug formulations for the treatment of Alzheimer's disease progression

RSC Advances, Год журнала: 2025, Номер 15(6), С. 4031 - 4078

Опубликована: Янв. 1, 2025

Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no effective disease-modifying treatments.

Язык: Английский

---

Biofilm-camouflaged Prussian blue synergistic mitochondrial mass enhancement for Alzheimer's disease based on Cu2+ chelation and photothermal therapy

Journal of Controlled Release, Год журнала: 2024, Номер 375, С. 269 - 284

Опубликована: Сен. 13, 2024

Язык: Английский

---

Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood–Brain Barrier Crossing Ability

Advanced Science, Год журнала: 2024, Номер 11(38)

Опубликована: Авг. 5, 2024

As a form of dementia, Alzheimer's disease (AD) suffers from no efficacious cure, yet AD treatment is still imperative, as it ameliorates the symptoms or prevents deteriorating maintains current status to longest extent. The human brain most sensitive and complex organ in body, which protected by blood-brain barrier (BBB). This induces difficulty curing drugs nanomaterials that are much inhibited reaching lesion site. Thus, BBB crossing capability drug delivery system remains significant challenge development neurological therapeutics. Fortunately, nano-enabled systems possess promising potential achieve multifunctional diagnostics/therapeutics against various targets owing their intriguing advantages nanocarriers, including easy multifunctionalization on surfaces, high surface-to-volume ratio with large payloads, ability cross BBB, making them capable conquering limitations conventional candidates. review, focuses diagnosis treatment, will provide an insightful vision conducive AD-related nanomaterials.

Язык: Английский

---

Erythrocyte membrane vesicles as drug delivery systems: A systematic review of preclinical studies on biodistribution and pharmacokinetics

Biomaterials Advances, Год журнала: 2025, Номер 170, С. 214234 - 214234

Опубликована: Фев. 14, 2025

This systematic review aims to summarize the development of erythrocyte membrane vesicles (EMVs) as drug delivery carriers, with a focus on elucidating their fate in terms biodistribution and pharmacokinetics preclinical studies. The PubMed database was systematically reviewed search for original peer-reviewed published studies use EMVs findings, following PRISMA guidelines. A total 142 articles matched selection criteria were included review. For each study, parameters extracted: type active pharmaceutical ingredient (API) encapsulated into EMVs, EMVs-API formulation method final particle size, surface modifications targeting, cell lines animal models used crucial treatment data, data finally, where applicable, about circulation time blood half-life. size did not vary significantly among different methods. complete list is provided. Circulation times half-life grouped per type. most commonly type, BALB/c mice, average EMV-API calculated be 10.4 h, all cases, up 10-fold increase observed compared that free API. Surface drastically change but improve target tissue accumulation. critical weaknesses analysed identified. Key points future are provided fill current knowledge gaps quality publications.

Язык: Английский

---

Research Progress on the Application of Polydopamine Nanoparticles in the Protective Treatment of the Brain in Ischemic Stroke

Advances in Clinical Medicine, Год журнала: 2025, Номер 15(02), С. 782 - 789

Опубликована: Янв. 1, 2025

Язык: Английский

---

ROS-related nanoparticles for the management of Alzheimer’s disease: Wielding the double-edged sword

Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 161784 - 161784

Опубликована: Март 1, 2025

Язык: Английский

---

Nanomaterial-based approaches to neurotoxin neutralization in neurodegenerative diseases

Nanomedicine, Год журнала: 2025, Номер unknown, С. 1 - 13

Опубликована: Апрель 3, 2025

Neurodegenerative diseases (NDs) are intricately linked to the accumulation of various neurotoxins, mainly including toxic proteins, inflammatory mediators, excess metal ions, and viral pathogens. Biological neutralization strategies that use agents competitively bind harmful substances thus inhibit their pathogenic activity hold promise for direct removal neurotoxins but face many limitations challenges in NDs. Nanomaterials provide a potential solution neurotoxin NDs due unique physicochemical biological properties. This review summarizes recent advancements nanomaterial-based approaches NDs, highlighting diverse design principles mechanisms action. We also discuss critical role targeted delivery optimize efficiency advantages combining different or introducing other therapeutic components exert synergistic effects. Furthermore, we reveal current future research directions aimed at paving way nanomedicine development based on treatment

Язык: Английский

---

Nitrogen-doped carbon dots as biocompatible fluorescent agents for labelling human red blood cells

Biomaterials Advances, Год журнала: 2025, Номер unknown, С. 214296 - 214296

Опубликована: Апрель 1, 2025

Язык: Английский

---

TGN peptide and erythrocyte membrane dual-modified selenium-doped carbon quantum dots for multifaceted treatment of Alzheimer’s disease

Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 163340 - 163340

Опубликована: Май 1, 2025

Язык: Английский

---

Multi-targeted engineered hybrid exosomes as Aβ nanoscavengers and inflammatory modulators for multi-pathway intervention in Alzheimer's disease

Biomaterials, Год журнала: 2025, Номер 322, С. 123403 - 123403

Опубликована: Май 9, 2025

Язык: Английский

---